Pfizer and Novo Nordisk's Obesity Drug Bidding War cover art

Pfizer and Novo Nordisk's Obesity Drug Bidding War

Pfizer and Novo Nordisk's Obesity Drug Bidding War

Listen for free

View show details

About this listen

 Describes an intensifying bidding war between Pfizer and Novo Nordisk over the obesity drug developer Metsera, which has escalated into a legal and financial showdown between the two pharmaceutical giants. Novo Nordisk recently made a $10 billion counteroffer, surpassing Pfizer’s previously accepted lower bid and prompting Pfizer to respond with an $8.1 billion revised offer alongside lawsuits accusing Metsera of breach of contract and antitrust violations.
A Delaware judge declined to halt the bidding process, noting that the competitive auction appeared to be benefiting Metsera’s shareholders, though legal challenges from Pfizer remain active. The acquisition is strategically pivotal: Pfizer views Metsera as a means to reestablish its footing in the fast-growing obesity market after recent setbacks, while Novo Nordisk sees the deal as essential to maintain its market dominance against fierce competition from Eli Lilly.
In parallel with the dispute, Pfizer raised its full-year profit outlook, signaling underlying business resilience despite slumping sales of its COVID-19 products.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.